$MCRB News

Seres Therapeutics Posts Early Data for Cancer Therapy Complication

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript

Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed

Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis

HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone Payments

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Seres Therapeutics Presents New Preclinical Data To Support Design, Potential Of SER-603 Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease

Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21

Seres Therapeutics to Present at CARB-X Investor Day

Seres Therapeutics: Q4 Earnings Snapshot

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates